高洋;孙昭;白春梅;
GAO Yang;SUN Zhao;BAI Chun-mei;Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院肿瘤内科

摘要(Abstract)：

鼻咽癌多与EB病毒感染相关,早期患者及时治疗后预后良好,但复发/转移性鼻咽癌治疗方式有限,预后不佳。近年来,免疫治疗在复发/转移性鼻咽癌中的研究十分广泛,其中免疫检查点抑制剂药物具有较好的疗效和良好的耐受性,引起临床广泛关注。程序性死亡受体-配体1(programmed death-ligand 1, PD-L1)表达状态、肿瘤突变负荷、循环EB病毒-DNA水平可能成为免疫检查点抑制剂疗效预测的生物标志物。本文将对免疫检查点抑制剂及其在复发/转移性鼻咽癌中的应用进行综述。
Nasopharyngeal carcinoma is mainly associated with Epstein-Barr virus(EBV) infection. The treatment of early nasopharyngeal carcinoma has a good prognosis, but the treatment options for recurrent/metastatic nasopharyngeal carcinoma are limited and the prognosis is poor. In recent years, there have been extensive studies on immunotherapy in advanced nasopharyngeal carcinoma, among which immune-checkpoint inhibitors are effective and causing clinical concern. Programmed death-ligand 1 expression status, tumor mutation burden and circulating EBV-DNA level may be biomarkers for predicting the efficacy of immune-checkpoint inhibitors. The applications of immune-checkpoint inhibitors in recurrent/metastatic nasopharyngeal carcinoma will be reviewed in this article.

关键词(KeyWords)： 鼻咽癌;免疫检查点抑制剂;生物标志物
nasopharyngeal carcinoma;immune-checkpoint inhibitor;biomarker

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院医学与健康科技创新工程(2016-12M-1-001)

作者(Author): 高洋;孙昭;白春梅;
GAO Yang;SUN Zhao;BAI Chun-mei;Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

Email:

DOI:

参考文献(References)：

• [1] Wei KR,Zheng RS,Zhang SW,et al.Nasopharyngeal carcinoma incidence and mortality in China,2013[J].Chin J Cancer,2017,36:90.
• [2] Chua MLK,Wee JTS,Hui EP,et al.Nasopharyngeal carcinoma[J].Lancet,2016,387:1012- 1024.
• [3] Ruuskanen M,Irjala H,Minn H,et al.Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma:A nationwide study in Finland[J].Head Neck,2019,41:349- 357.
• [4] Blanchard P,Lee A,Marguet S,et al.Chemotherapy and radiotherapy in nasopharyngeal carcinoma:an update of the MAC-NPC meta-analysis[J].Lancet Oncol,2015,16:645- 655.
• [5] Yang L,Hong SD,Wang Y,et al.Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy[J].Sci Rep,2015,5:15638.
• [6] Perri F,Della VSG,Caponigro F,et al.Management of recurrent nasopharyngeal carcinoma:current perspectives[J].Onco Targets Ther,2019,12:1583- 1591.
• [7] Le QT,Colevas AD,O'Sullivan B,et al.Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy[J].J Natl Cancer Inst,2019,111:655- 663.
• [8] Larbcharoensub N,Mahaprom K,Jiarpinitnun C,et al.Characterization of PD-L1 and PD- 1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma[J].Am J Clin Oncol,2018,41:1204- 1210.
• [9] Walker LSK,Sansom DM.The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses[J].Nat Rev Immunol,2011,11:852- 863.
• [10] Chen BJ,Chapuy B,Ouyang J,et al.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies[J].Clin Cancer Res,2013,19:3462- 3473.
• [11] Fang WF,Zhang JW,Hong SD,et al.EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma:Implications for oncotargeted therapy[J].Oncotarget,2014,5:12189- 12202.
• [12] Hsu MC,Hsiao JR,Chang KC,et al.Increase of programmed death- 1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J].Mod Pathol,2010,23:1393- 1403.
• [13] Xiao M,Qi F,Chen X,et al.Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population[J].Int J Immunogenet,2010,37:27- 32.
• [14] Hsu C,Lee SH,Ejadi S,et al.Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma:Results of the KEYNOTE- 028 Study[J].J Clin Oncol,2017,35:4050- 4056.
• [15] Ma B,Lim WT,Goh BC,et al.Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma:An International,Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI- 9742)[J].J Clin Oncol,2018,36:1412- 1418.
• [16] Fang WF,Yang YP,Ma YX,et al.Camrelizumab (SHR- 1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm,phase 1 trials[J].Lancet Oncol,2018,19:1338- 1350.
• [17] Zhou YJ,Shi DB,Miao JJ,et al.PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD- 1 and EBV-DNA load[J].Sci Rep,2017,7:43627.
• [18] Fang WF,Zhang JW,Hong SD,et al.EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma:Implications for oncotargeted therapy[J].Oncotarget,2014,5:12189- 12202.
• [19] Ferris RL,Blumenschein GJ,Fayette J,et al.Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck:2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J].Oral Oncol,2018,81:45- 51.
• [20] Harrington KJ,Ferris RL,Blumenschein GJ,et al.Nivolumab versus standard,single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141):health-related quality-of-life results from a randomised,phase 3 trial[J].Lancet Oncol,2017,18:1104- 1115.
• [21] Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE- 012):an open-label,multicentre,phase 1b trial[J].Lancet Oncol,2016,17:956- 965.
• [22] Liu MB,Han SJ,Zheng B,et al.Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States[J].Cancer Manag Res,2019,11:9483- 9493.
• [23] Cohen EEW,Soulieres D,Le Tourneau C,et al.Pembroli-zumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE- 040):a randomised,open-label,phase 3 study[J].Lancet,2019,393:156- 167.
• [24] Kim KY,Le QT,Yom SS,et al.Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients[J].Int J Radiat Oncol Biol Phys,2017,98:996- 1001.
• [25] Wang WY,Lin TY,Twu CW,et al.Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA[J].Oncotarget,2016,7:42608- 42616.
• [26] Chan ATC,Hui EP,Ngan RKC,et al.Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy:A Randomized Controlled Trial[J].J Clin Oncol,2018.doi:10.1200/JCO.2018.77.7847.
• [27] Johnson DB,Frampton GM,Rioth MJ,et al.Targeted Next Generation Sequencing Identifies Markers of Response to PD- 1 Blockade[J].Cancer Immunol Res,2016,4:959- 967.
• [28] Rizvi NA,Hellmann MD,Snyder A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD- 1 blockade in non-small cell lung cancer[J].Science,2015,348:124- 128.
• [29] Rosenberg JE,Hoffman-Censits J,Powles T,et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm,multicentre,phase 2 trial[J].Lancet,2016,387:1909- 1920.
• [30] Samstein RM,Lee CH,Shoushtari AN,et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J].Nat Genet,2019,51:202- 206.
• [31] Brown SD,Warren RL,Gibb EA,et al.Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival[J].Genome Res,2014,24:743- 750.
• [32] Cesano A,Warren S.Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic[J].Biomedicines,2018,6:14.